Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
Hepatitis C Epidemic Erodes a Village’s Reputation for Longevity
Trump Says Apple’s Cook Concerned About Losing Edge to Samsung With Tariffs
Xiaomi, Oppo, Vivo to Launch Cross-Platform ‘AirDrop’
LATEST
As China Rolls Out Commercial 5G, Experts Are Split on Take-Up Speed
Interest Rate Reform May Benefit Bigger Companies More, Economists Say
Sanctions-Hit Huawei to Open New R&D Centers in Russia: Reports
Xiaomi, Oppo, Vivo to Launch Cross-Platform ‘AirDrop’
Trump Says Apple’s Cook Concerned About Losing Edge to Samsung With Tariffs
Hepatitis C Epidemic Erodes a Village’s Reputation for Longevity
Cathay Pacific CEO Hogg Resigns Amid Hong Kong Protests
Ninebot’s New Scooter Can Drive Itself Back to Charging Stations
Oppo to Unveil New Smartphone With 20x Zoom
Chinese Companies Usher in Age of Synthetic Meat
Record-Smashing Chinese Animation to Get Overseas Releases
WTO to Arbitrate China’s Complaints About U.S. Solar-Cell Tariffs
Vipshop Stock Soars After Q2 Results Beat Expectations
Japan Replaces China as Largest Holder of U.S. Government Debt
Huawei’s First 5G Commercial Phone Gets Warm Response Despite Limited Networks
AI Startup Plans IPO at Value of at Least $1 Billion — in China
Alibaba Q2 Revenue Jumps 42%, Beating Estimates But Slower Than Year Earlier
Baidu’s $66 Billion Dive Knocks It Out of China’s Internet Top 5
Beijing Grants Foreign Investors Wider Access to Entertainment Industry
Tencent-Backed Maoyan Turns Profit on Strong Ad Growth
Chinese DNA Sequencing Firm BGI Faces Legal Battle with Illumina

By Wang Luyao and Han Wei / May 24, 2019 02:59 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese genomics giant BGI Group said it is prepared in the face of rising legal disputes in Europe and may resort to counterclaims to fight patent infringement allegations.

BGI is “actively responding to recent patent disputes and will take corresponding legal actions,” BGI said in a statement to Caixin Thursday, adding that it “will not rule out the use of legal weapons such as counterclaims to protect its legal rights.”

BGI’s subsidiary BGI Europe was sued by Illumina Inc. in Denmark on alleged patent infringement last week. The complaint alleged BGI's sequencing products and related sequencing chemistry reagents infringe on Illumina's European patent.

The case followed another infringement suit filed by Illumina in Germany against another BGI subsidiary, Latvia MGI Tech, in March.

In the statement, BGI said it is confident in its own technology, which cost billions of yuan to develop and “broke the market monopoly in the upstream genome sequencing market.”

When interviewed by Caixin earlier this month on whether Illumina will file more suits against BGI outside Europe, the company’s Chief Commercial Officer Mark Van Oene said Illumina will continue pursuing patent protection, without elaborating.

Established in 1999, BGI was a client of Illumina’s sequencing equipment but has started to develop its own devices after purchasing U.S. genomics company Complete Genomics in 2012.

Related: BGI Genomics’ Profits Slip As Questions Linger About Its Services


Share this article
Open WeChat and scan the QR code
Copyright © 2019 Caixin Global Limited. All Rights Reserved.